![](https://thepharmadata.com/wp-content/uploads/2024/06/FDA-Approves-Bristol-Myers-Squibbs-Breyanzi-for-RelapsedRefractory-Mantle-Cell-Lymphoma-CAR-T-Cell-Therapy-768x512.webp)
FDA Recognizes Astellas’ Renewed Submission of Biologics License Application for Zolbetuximab and Establishes Revised Action Deadline
Today, Astellas announced that the U.S. Food and Drug Administration (FDA) has acknowledged the resubmission of the Biologics License Application (BLA) for zolbetuximab, a groundbreaking investigational monoclonal antibody targeting claudin (CLDN) 18.2. This resubmission is intended for the first-line treatment…